Market Access News | pharmaphorum

News

Grail cancer test gets lukewarm backing from FDA adcomm

FDA expert advisors voted in favour of Grail's Galleri blood test for detecting multiple cancers, but some expressed misgivings about its efficacy.

News

Pharma leaders urge Europe to halt 'slow agony' of decline

Europe's top pharma firms have called on governments to take action to change the region's story from one of decay to one of "renewal and resilience."

News

UK first country to launch CSL's trivalent flu shot Aujemflu

CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.

News

Advocacy group pokes holes in Trump's MFN pricing claims

Public Citizen says claims for the drug price savings that are being delivered by Trump's Most-Favoured Nation deals with pharma are "a mirage."

News

AZ's gMG drug Klygefa nears EU approval

AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.

News

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Grail cancer test gets lukewarm backing from FDA adcomm

Pharma leaders urge Europe to halt 'slow agony' of decline

UK first country to launch CSL's trivalent flu shot Aujemflu

Advocacy group pokes holes in Trump's MFN pricing claims

AZ's gMG drug Klygefa nears EU approval

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks